Introduction
What causes pulmonary embolism? In most cases, pulmonary embolism develops when a blood clot forms elsewhere in the body, usually in a deep vein of the leg or pelvis, then breaks loose, travels through the bloodstream, and lodges in the arteries of the lungs. The event is not random; it arises from specific biological processes that promote clot formation, clot dislodgement, and vascular blockage. The major causes can be understood in three broad groups: conditions that make blood more likely to clot, circumstances that slow blood flow or damage vessels, and underlying disorders that generate clots in the veins.
To understand pulmonary embolism, it is helpful to begin with the normal relationship between blood clotting and circulation. The body must be able to stop bleeding after injury, but clotting is tightly regulated so that clots form only where they are needed. Pulmonary embolism occurs when this balance fails, allowing a clot to form in the venous system and then travel to the lungs, where it obstructs blood flow and interferes with oxygen exchange.
Biological Mechanisms Behind the Condition
Pulmonary embolism usually begins with deep vein thrombosis, the formation of a clot in a deep vein, most often in the lower limbs. A clot forms when platelets and clotting proteins are activated inappropriately inside a vein. Once formed, part of the clot may detach and become an embolus, which is a traveling intravascular mass. Because venous blood returns to the heart and then to the lungs, the embolus naturally follows this pathway and can become trapped in the pulmonary arteries.
The process that makes clot formation possible is often explained by Virchow’s triad: slowed blood flow, injury to the vessel wall, and a tendency for the blood to clot too easily. When blood flow slows, clotting factors remain in contact with the vessel lining longer than they normally would, which increases the chance of clot formation. If the vein wall is damaged, the exposed surface can trigger coagulation. If the blood has become hypercoagulable, the clotting system is more easily activated and less easily restrained. Pulmonary embolism reflects the end result of one or more of these processes operating strongly enough to create a clinically significant clot.
Once a clot reaches the lung, the consequences depend on its size and location. Large emboli can block major pulmonary arteries, abruptly raising pressure in the right side of the heart and reducing blood flow to the lungs. Smaller emboli may lodge in peripheral branches, causing less dramatic obstruction but still impairing oxygenation and lung perfusion. The underlying cause, however, remains the same: a venous thrombus has formed, broken free, and moved into the pulmonary circulation.
Primary Causes of Pulmonary embolism
Deep vein thrombosis is the main immediate cause of pulmonary embolism. A clot in the deep veins of the leg or pelvis is the usual source because these veins carry large volumes of blood back to the heart and are vulnerable to pooling when a person is immobile. As the clot organizes and grows, it may remain attached to the vein wall or may fragment. If a fragment dislodges, it can pass through the right side of the heart and enter the pulmonary arteries. In this sense, pulmonary embolism is often the complication of an earlier venous clot rather than a separate disease arising in the lungs themselves.
Prolonged immobility is one of the strongest contributors to clot formation. When a person is bedridden, confined after surgery, or sitting for long periods, the calf muscles do not contract regularly enough to help drive venous blood upward. Venous stasis develops, especially in the deep veins of the legs. Slow-moving blood allows clotting factors to accumulate and makes the endothelium, the inner lining of the vein, more favorable to thrombus formation. A clot formed under these conditions may remain silent until part of it breaks off and travels to the lungs.
Recent surgery or trauma also promotes pulmonary embolism. Surgery, especially orthopedic or pelvic procedures, can injure blood vessels directly and can trigger a strong clotting response because tissue damage releases substances that activate coagulation. Trauma has a similar effect by disrupting vessel integrity and creating inflammation. In addition, the recovery period after surgery or injury often involves reduced mobility, which further increases venous stasis. These effects often overlap, making postoperative patients a high-risk group for venous thromboembolism.
Cancer is another major cause. Some tumors produce procoagulant substances that shift the blood toward clotting. Cancer can also compress veins, limit movement, and provoke inflammatory changes that alter the vascular environment. Certain chemotherapy drugs and central venous catheters can add further risk. The result is a state in which thrombi form more readily and can migrate to the pulmonary arteries. In some cases, recurrent or unexplained pulmonary embolism may be the first clue to an underlying malignancy.
Inherited or acquired clotting disorders can predispose a person to pulmonary embolism by making the coagulation system unusually active. Genetic mutations such as factor V Leiden or prothrombin gene mutations interfere with the body’s natural checks on clot formation. Acquired disorders, such as antiphospholipid syndrome, can also increase clotting tendency through immune-mediated effects on coagulation pathways. In both cases, the blood reaches a hypercoagulable state in which clots can form with less provocation than usual.
Contributing Risk Factors
Several additional factors raise the likelihood of pulmonary embolism by affecting blood flow, vessel integrity, or coagulation balance. Genetic influences can alter how strongly the clotting system responds to injury or stasis. Some people inherit mutations that make clotting proteins more active, while others have deficiencies in natural anticoagulant proteins such as protein C, protein S, or antithrombin. These inherited changes do not always produce clots on their own, but they lower the threshold at which a thrombus can develop.
Hormonal changes are important because estrogen can increase coagulation factor levels and reduce some natural anticoagulant activity. Pregnancy, the postpartum period, and estrogen-containing contraceptives or hormone therapy can therefore raise clotting risk. Pregnancy also compresses pelvic veins and reduces venous return from the legs, which promotes stasis. These hormonal and mechanical effects together create a biologic environment that favors clot formation and, potentially, pulmonary embolism.
Lifestyle factors such as obesity and smoking also contribute. Obesity can impair venous return, increase inflammatory signaling, and raise levels of procoagulant factors. Smoking damages the endothelium and promotes a more inflammatory, prothrombotic state. Long-distance travel, especially when combined with dehydration or limited leg movement, can increase stasis in the lower extremity veins. Dehydration itself may concentrate blood components and make clotting more likely, although it is usually a minor factor compared with major medical risks.
Infections and systemic inflammation can also contribute. Severe infection can activate the immune system in ways that stimulate coagulation, a phenomenon sometimes referred to as inflammation-associated thrombosis. Inflammation alters endothelial behavior, increases clotting factor activity, and may suppress natural anticoagulant pathways. Serious illness may also lead to immobility, amplifying the risk further. In this way, infection can contribute to pulmonary embolism both through direct effects on coagulation and through indirect effects on circulation.
How Multiple Factors May Interact
Pulmonary embolism often results from more than one cause acting together. A person may have a modest inherited tendency toward clotting, then undergo surgery and remain immobile for several days. Each factor alone may only slightly increase risk, but combined they can produce a much stronger shift toward thrombosis. This interaction reflects the way the vascular system, clotting cascade, and inflammatory pathways influence one another.
For example, immobility slows venous blood flow, which permits clotting proteins to remain concentrated. If the endothelium is also inflamed from surgery or infection, it becomes more thrombogenic. If the individual has a genetic defect that weakens anticoagulant control, the body is even less able to prevent clot expansion. The clot that forms in this setting is more likely to grow large enough to detach and embolize. Pulmonary embolism is therefore often the outcome of a chain of biologically reinforcing events rather than a single isolated trigger.
Variations in Causes Between Individuals
The causes of pulmonary embolism differ between individuals because susceptibility is shaped by genetics, age, health status, and exposure history. Younger people with a clotting disorder may develop pulmonary embolism after a relatively small trigger, such as a brief period of immobility or use of hormonal contraception. Older adults more often develop it in the context of surgery, cancer, heart failure, or general frailty, where multiple acquired risks accumulate over time.
Health status matters because chronic disease can alter blood flow and coagulation in different ways. A person with advanced heart or lung disease may have reduced activity and poorer circulation, while someone with inflammatory disease may have persistently activated clotting pathways. Environmental exposure also differs among individuals. A person who has long-haul travel, prolonged desk work, or repeated hospitalization may face more opportunities for venous stasis than someone with a more active routine. These differences help explain why pulmonary embolism can appear after very different circumstances in different patients.
Conditions or Disorders That Can Lead to Pulmonary embolism
Several medical conditions can directly or indirectly lead to pulmonary embolism. Deep vein thrombosis is the most direct precursor, but it is often itself the consequence of another disorder. Cancer can create a persistent hypercoagulable state through tumor-related inflammation, tissue factor expression, and reduced mobility. Heart failure can slow circulation and contribute to venous stasis, while stroke or other disabling neurologic conditions may reduce movement enough to permit clot formation in the legs.
Inflammatory autoimmune disorders such as antiphospholipid syndrome are especially important because they can alter clotting at a systemic level. In antiphospholipid syndrome, antibodies promote thrombosis by interfering with phospholipid-dependent coagulation regulation and by activating cells involved in clot formation. Nephrotic syndrome can also increase clotting risk because protein loss in the urine may include natural anticoagulants, which reduces the body’s ability to restrain clot formation. Major infections and sepsis can trigger a strong inflammatory response that shifts the blood toward thrombosis.
Some conditions produce emboli through additional mechanisms. Fat emboli after major long-bone fractures, air emboli from certain procedures, and amniotic fluid embolism in obstetric emergencies are not the classic venous thromboembolic form of pulmonary embolism, but they illustrate the broader principle that material entering the pulmonary circulation can obstruct blood flow. In everyday clinical use, however, pulmonary embolism usually refers to a thrombus originating in the venous system.
Conclusion
Pulmonary embolism develops when a clot forms in the venous system, detaches, and travels to the pulmonary arteries, where it blocks blood flow. The key biological forces behind this process are venous stasis, vessel injury, and hypercoagulability. Deep vein thrombosis, immobility, surgery, trauma, cancer, and inherited or acquired clotting disorders are among the most important causes. Hormonal changes, smoking, obesity, infection, and chronic illness can further increase risk by shifting the balance toward thrombosis.
Understanding the causes of pulmonary embolism means understanding how circulation, clotting, inflammation, and vascular health interact. The condition is not simply a clot in the lung; it is usually the final step in a chain of events that begins elsewhere in the body. That biological sequence explains why some people are more vulnerable than others and why the same condition can arise through different pathways in different individuals.